{"schema_version":"secwatch.filing_event.v1","accession":"0001824293-26-000017","form_type":"8-K","ticker":"GRI","cik":"0001824293","company_name":"GRI Bio, Inc.","filed_at":"2026-01-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.370326+00:00","generated_at":"2026-05-16T07:05:27.751414+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"GRI Bio reports positive Phase 2a gene expression data for GRI-0621 in IPF","bullets":["Phase 2a gene expression data shows significant improvements in lung injury, fibroblast activation, and fibrosis-resolution genes vs placebo.","Data support basement membrane repair and AT2-to-AT1 epithelial cell transition, suggesting lung regeneration.","GRI-0621 met primary safety endpoint and multiple secondary endpoints; exploratory FVC improved vs standard of care.","CEO states data exceed expectations, reinforcing potential as a disease-modifying therapy for IPF."],"urls":{"canonical":"https://secwatch.observer/filing/0001824293-26-000017","json":"https://secwatch.observer/filing/0001824293-26-000017.json","markdown":"https://secwatch.observer/filing/0001824293-26-000017.md","text":"https://secwatch.observer/filing/0001824293-26-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824293/000182429326000017/0001824293-26-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824293/000182429326000017/val-20260128.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T07:05:27.751414+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}